Data / Research funding / Vaccine Related - AIDS
Vaccine Related - AIDS: 228 NIH awards ($2.3B) to 95 organizations
228 NIH awards ($2.3B) in the NIH spending category Vaccine Related - AIDS, to 95 organizations, read 2026-11-03. NIH fiscal years 2021 to 2025.
SpecStream is the live web data engine for teams and agents. It reads the NIH and NSF award files each time the agencies update them, and this page is that reading, joined to the open federal funding opportunities on Grants.gov. Ask for the awards you track by topic, organization or state and new awards arrive in your sheet, CRM, Slack or agent as the agencies publish them.
- Topic
- NIH spending category
Awards
228 awards in the window.
| Award | Agency | Institute or division | Fiscal year | Amount in window | Start | End | Principal investigator | Source |
|---|---|---|---|---|---|---|---|---|
| HIV Vaccines Clinical Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $244,071,463 | June 29, 2006 | November 30, 2027 | COREY, LAWRENCE | reporter.nih.gov |
| HIV Prevention Trials Network Leadership and Operations Center | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $213,590,410 | June 1, 2006 | November 30, 2027 | COHEN, MYRON SCOTT | reporter.nih.gov |
| HIV and Other Infectious Diseases Clinical Research Support Services (CRSS) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $198,645,463 | August 15, 2025 | August 14, 2026 | STOKES, BAMBRA | reporter.nih.gov |
| HIV Vaccine Trials Network Laboratory Center | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $177,480,054 | June 29, 2006 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| SDMC: HIV Vaccine Trials Network | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $156,744,802 | June 29, 2006 | November 30, 2027 | GILBERT, PETER B. | reporter.nih.gov |
| Consortium for HIV/AIDS Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $145,502,241 | July 1, 2019 | June 30, 2026 | BURTON, DENNIS R. | reporter.nih.gov |
| Induction of protective antibodies for HIV vaccine development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $143,048,158 | July 15, 2019 | June 30, 2026 | HAYNES, BARTON F. | reporter.nih.gov |
| Consortium for Advancing Management and Prevention of Cancer in People with HIV | NIH | National Cancer Institute | 2021 to 2025 | $106,635,299 | August 29, 2006 | August 31, 2030 | SPARANO, JOSEPH A. | reporter.nih.gov |
| DAIDS Quality Assurance, Quality Control and Inspection Readiness Support Services | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $51,529,857 | April 17, 2025 | April 16, 2026 | reporter.nih.gov | |
| Clinical Research Products Management Center (CRPMC) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $46,852,833 | June 16, 2025 | June 15, 2026 | REMGSAMAI-NHE, CARINA | reporter.nih.gov |
| Production of Aluminum Based Adjuvants | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $34,078,534 | September 20, 2017 | December 31, 2026 | MACK, FRED | reporter.nih.gov |
| REACH: Research Enterprise to Advance a Cure for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $27,533,114 | August 16, 2021 | April 30, 2027 | JONES, R. BRAD | reporter.nih.gov |
| B and T Cell Biology of Protection from and Eradication of SIV/SHIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $26,314,793 | June 1, 2022 | May 31, 2027 | HUNTER, ERIC | reporter.nih.gov |
| SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $21,986,953 | September 2, 2022 | June 30, 2027 | WILLIAMS, WILTON B | reporter.nih.gov |
| UZ-UCSF CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,624,239 | September 9, 2025 | November 30, 2027 | CHIRENJE, ZVAVAHERA MIKE | reporter.nih.gov |
| Boston HIV CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $21,445,869 | January 15, 2007 | November 30, 2027 | KURITZKES, DANIEL R. | reporter.nih.gov |
| Emory-CDC CTU | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,972,899 | December 1, 2024 | November 30, 2027 | KELLEY, COLLEEN F | reporter.nih.gov |
| University of Pennsylvania HIV Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $16,198,927 | February 1, 2007 | November 30, 2027 | FRANK, IAN | reporter.nih.gov |
| PERU Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,506,525 | December 1, 2024 | November 30, 2027 | SANCHEZ, JORGE LUIS | reporter.nih.gov |
| PHRU-Setshaba Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $15,110,381 | December 1, 2024 | November 30, 2027 | GRAY, GLENDA E | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $14,042,495 | April 1, 2020 | March 31, 2027 | AYE, PYONE | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Maintenance of Nonhuman Primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,765,907 | April 1, 2020 | March 31, 2027 | VILLINGER, FRANCOIS | reporter.nih.gov |
| HIV/AIDS Clinical Trials Units University of Cape Town CTU 2020 to 2027 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,518,599 | April 1, 2007 | November 30, 2027 | BEKKER, LINDA-GAIL | reporter.nih.gov |
| Pitt-Ohio State Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $13,065,770 | February 1, 2007 | November 30, 2027 | RIDDLER, SHARON | reporter.nih.gov |
| Vanderbilt HIV Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,733,650 | February 1, 2007 | November 30, 2027 | HAAS, DAVID W | reporter.nih.gov |
| Columbia Collaborative HIV/AIDS Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $12,286,513 | February 1, 2007 | November 30, 2027 | SOBIESZCZYK, MAGDALENA ELZBIETA | reporter.nih.gov |
| Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $11,597,222 | December 1, 2024 | November 30, 2025 | DENNY, TOM | reporter.nih.gov |
| Reagent Resource Support Program for AIDS Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $11,522,629 | April 8, 2018 | April 7, 2025 | FREMONT, VALERIE | reporter.nih.gov |
| KwaZulu-Natal Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,302,268 | December 1, 2024 | November 30, 2027 | ABDOOL KARIM, QUARRAISHA | reporter.nih.gov |
| The Johns Hopkins University-Blantyre Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $11,246,510 | February 15, 2007 | November 30, 2027 | TAHA, TAHA E | reporter.nih.gov |
| Nonhuman Primate (NHP) Core Functional Genomics Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,303,422 | July 1, 2019 | June 30, 2020 | GALE, MICHAEL | reporter.nih.gov |
| University of Rochester HIV/AIDS Clinical Trials Unit Administrative Supplement | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $10,156,163 | August 26, 2025 | November 30, 2027 | KEEFER, MICHAEL C | reporter.nih.gov |
| Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $10,129,006 | March 30, 2024 | March 29, 2025 | SHEN, SHAUNNA | reporter.nih.gov |
| The Military HIV Research Program (MHRP) Clinical Trial Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $9,910,676 | December 10, 2013 | November 30, 2027 | ROBB, MERLIN L | reporter.nih.gov |
| A-Z Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,989,738 | February 1, 2007 | November 30, 2027 | GOEPFERT, PAUL A. | reporter.nih.gov |
| Simian Vaccine Evaluation Unit: Core Activities - Administrative and Technical Support | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,478,988 | April 1, 2020 | March 31, 2027 | LEWIS, MARK | reporter.nih.gov |
| San Francisco Bay Clinical Trials Unit (CTU) | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,314,128 | March 2, 2007 | November 30, 2027 | BUCHBINDER, SUSAN | reporter.nih.gov |
| The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit. | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $8,239,326 | January 15, 2008 | November 30, 2027 | GRINSZTEJN, BEATRIZ | reporter.nih.gov |
| cGMP Manufacture, Fill-Finish, Release, Analytical and Stability Testing and Stability Program of a Nanoparticle Based HIV Envelope Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $8,013,603 | August 30, 2022 | August 29, 2030 | HASSELL, THOMAS | reporter.nih.gov |
| External Quality Assurance Program Oversight Laboratory (EQAPOL) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $7,902,910 | September 30, 2024 | September 29, 2031 | DENNY, THOMAS | reporter.nih.gov |
| Seattle Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $7,698,581 | February 1, 2007 | November 30, 2027 | MCELRATH, MARGARET JULIANA | reporter.nih.gov |
| Aurum Clinical Trials Unit | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,678,965 | December 1, 2020 | November 30, 2027 | CHURCHYARD, GAVIN JOHN | reporter.nih.gov |
| Design and testing of immunogens to elicit 10E8-like broadly neutralizing antibodies against HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $6,090,710 | July 8, 2019 | August 31, 2029 | SCHIFFNER, TORBEN | reporter.nih.gov |
| Cellular Immunology Core Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $5,413,068 | June 1, 2025 | May 31, 2026 | KAUR, AMITINDER | reporter.nih.gov |
| HIV-1 Q23.17 Env: Engineering a novel immunogen to elicit broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $5,173,076 | June 23, 2021 | May 31, 2026 | SHAW, GEORGE M | reporter.nih.gov |
| High-throughput proteomics using submicroliter amounts of plasma for comprehensive assessment of the immune status | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $5,147,391 | April 9, 2020 | March 31, 2026 | STEEN, HANNO | reporter.nih.gov |
| Antigen recognition and activation of HIV-specific B cell antigen receptors | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,911,145 | March 20, 2019 | July 31, 2029 | ALAM, S. MUNIR | reporter.nih.gov |
| HIV-1 Fusion Peptide-directed Vaccine Design Using Virus-like Particles | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,825,382 | March 1, 2021 | February 28, 2027 | KONG, RUI | reporter.nih.gov |
| Durable HIV Vaccine Targeting Mucosal Epithelium | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $4,751,308 | August 1, 2022 | July 31, 2027 | GAUDUIN, MARIE-CLAIRE ELISABETH | reporter.nih.gov |
| Leveraging novel pediatric SHIVs to identify biomarkers of prophylactic efficacy of bnAb against breast milk HIV transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $4,686,370 | September 25, 2025 | August 31, 2029 | FOUDA AMOU OU, GENEVIEVE GINY | reporter.nih.gov |
| Population genotyping of the germline immunoglobulin repertoire in AIDS-designated rhesus macaque breeding colonies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,657,141 | May 1, 2021 | August 31, 2030 | BOSINGER, STEVEN EDWARD | reporter.nih.gov |
| Elicitation of HIV Broadly Neutralizing Antibodies from Engineered B cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,634,490 | July 1, 2021 | December 31, 2026 | VOSS, JAMES EVEN | reporter.nih.gov |
| Maximizing germinal centers and somatic hypermutation to HIV Env immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,431,323 | February 1, 2016 | January 31, 2026 | CROTTY, SHANE P | reporter.nih.gov |
| Dissecting Polyclonal Sera to Reveal Correlates of Productive Immune Responses to HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,391,888 | March 16, 2018 | February 29, 2028 | WARD, ANDREW BARRETT | reporter.nih.gov |
| Optimizing glycan shield coverage, germline B cell receptor binding and epitope diversity of V2-apex targeted HIV-1 Env immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $4,308,687 | September 19, 2019 | August 31, 2029 | HAHN, BEATRICE H | reporter.nih.gov |
| Inducing HIV-1 NAb Breadth by Native Trimer Prime-Boost Vaccination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $4,133,062 | March 1, 2011 | May 31, 2025 | BINLEY, JAMES M | reporter.nih.gov |
| Rational Systemic Characterization and Selection of Adjuvants for HIV Vaccine Candidates (R-CASA) | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,983,710 | August 1, 2025 | July 31, 2026 | CHATTERJEE, ARNAB KUMAR | reporter.nih.gov |
| Tracking the evolutionary trajectory of neutralizing antibodies following BG505 SOSIP immunization | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,907,608 | June 16, 2023 | May 31, 2027 | DERDEYN, CYNTHIA ANN | reporter.nih.gov |
| Development of multi-modal single-cell technology to dissect epitope specificity to HIV | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,892,813 | June 26, 2015 | May 31, 2026 | BOSINGER, STEVEN EDWARD | reporter.nih.gov |
| Immune Dysfunction in HIV+ Opioid Users | NIH | National Institute on Drug Abuse | 2021 to 2025 | $3,823,539 | April 15, 2020 | January 31, 2027 | PAHWA, SAVITA | reporter.nih.gov |
| Role of ncRNA Surveillance Complex "RNA Exosome" in Class Switch Recombination and Somatic Hypermutation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,761,466 | May 7, 2012 | April 30, 2027 | BASU, UTTIYA | reporter.nih.gov |
| Production of cGMP Native Flexibly Linked HIV-1 Envelope Protein | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,709,483 | September 12, 2016 | March 31, 2028 | FOUTS, TIMOTHY | reporter.nih.gov |
| Nonhuman Primate Core Virology Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,695,898 | December 22, 2017 | December 14, 2024 | DENNY, THOMAS | reporter.nih.gov |
| Using immune complex vaccines to optimize antibody responses to HIV Env | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,657,831 | March 12, 2020 | February 28, 2027 | HIOE, CATARINA E | reporter.nih.gov |
| Optimizing AAV delivery of bNAbs for HIV prevention | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,607,044 | November 24, 2021 | October 31, 2026 | GARDNER, MATTHEW RYAN | reporter.nih.gov |
| Mechanisms of B cell responses to particulate antigens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,582,696 | July 1, 2021 | June 30, 2027 | CHENG, WEI | reporter.nih.gov |
| Transforming HIV vaccine design with a hybrid technology that leverages features of mRNA and protein nanoparticle platforms | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,559,750 | September 26, 2025 | August 31, 2029 | HOFFMANN, MAGNUS ADRIAN GERO | reporter.nih.gov |
| Assessing the effects of oral pre-exposure prophylaxis on pharmacokinetics of monoclonal and vaccine-induced antibodies among women vulnerable to HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,554,273 | September 12, 2025 | August 31, 2029 | HUANG, YUNDA | reporter.nih.gov |
| Antibody dependent cellular cytotoxicity and HIV-1 mother to child transmission | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,515,485 | September 19, 2022 | July 31, 2027 | SAGAR, MANISH | reporter.nih.gov |
| Structural characterization of Fab-dimerized glycan-reactive antibodies that neutralize HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,416,984 | September 17, 2021 | August 31, 2026 | ACHARYA, PRIYAMVADA | reporter.nih.gov |
| Vaccination with invariant MHC-II-linked accessory antigens for protection from HIV infection | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,308,638 | September 23, 2020 | August 31, 2025 | VEAZEY, RONALD S. | reporter.nih.gov |
| Natural killer cell regulation of the germinal center HIV neutralizing antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,284,070 | December 1, 2019 | November 30, 2025 | BRADLEY, TODD CHRISTOPHER | reporter.nih.gov |
| Designing HIV-1 envelope immunogens to maximize neutralization breadth through use of multiple founder envelope antigens | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $3,259,509 | June 20, 2023 | May 31, 2027 | BOLTON, DIANE L. | reporter.nih.gov |
| Combining germline-targeting, B cell immunofocusing and Env-Ab coevolution strategies to induce HIV Envelope V2-apex broadly neutralizing antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $3,245,040 | April 1, 2021 | May 31, 2027 | ANDRABI, RAIEES AHMAD | reporter.nih.gov |
| Reverse Vaccinology in SHIV Infected Macaques as a Molecular Guide for HIV-1 Vaccine Design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,216,371 | March 11, 2021 | February 28, 2026 | SHAW, GEORGE M | reporter.nih.gov |
| HIV-1 vaccine-elicited antibodies target envelope glycans | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $3,044,804 | June 15, 2015 | July 31, 2025 | SAUNDERS, KEVIN O | reporter.nih.gov |
| Clonal Dynamics of the antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $3,017,736 | January 1, 2017 | December 31, 2026 | VICTORA, GABRIEL D | reporter.nih.gov |
| Design of single-shot sequential immunization regimens for HIV using atomic layer deposition technology. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $3,017,032 | August 8, 2025 | July 31, 2029 | IRVINE, DARRELL J | reporter.nih.gov |
| The role of Trained Immunity and Mitochondrial dysfunction on INnate immunity in children and adolescents aGing with PHIV (TIMING-PHIV) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $3,016,481 | March 21, 2022 | February 28, 2027 | FUNDERBURG, NICHOLAS T. | reporter.nih.gov |
| eCD4-Ig for preventing and treating obstetric HIV infection | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,999,760 | August 13, 2020 | May 31, 2026 | MARTINS, MAURICIO DE AGUIAR | reporter.nih.gov |
| Defining the biological relevance of HIV specific HLA-E restricted CD8 T cell responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,951,992 | April 16, 2021 | March 31, 2026 | GOEPFERT, PAUL A. | reporter.nih.gov |
| Multiomics characterization, induction, and elimination of the HIV gut reservoir | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2022 to 2025 | $2,937,487 | July 15, 2022 | April 30, 2027 | ROAN, NADIA R | reporter.nih.gov |
| Role of CXCR4 in immunoglobulin light chain recombination | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,897,990 | March 8, 2021 | February 28, 2026 | CLARK, MARCUS RAMSAY | reporter.nih.gov |
| Dissecting the Conformational Flexibility of HIV-1 Envelope Glycoproteins | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,867,050 | June 15, 2022 | May 31, 2027 | HERSCHHORN, ALON | reporter.nih.gov |
| AAV-mediated delivery of eCD4-Ig for prevention and treatment of perinatal HIV infection | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,809,667 | August 7, 2020 | May 31, 2026 | MARTINS, MAURICIO DE AGUIAR | reporter.nih.gov |
| Inflammation-driven T Cell Responses and their Dichotomous Effect on Host Immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,806,788 | December 1, 2016 | July 31, 2027 | PRLIC, MARTIN | reporter.nih.gov |
| Novel bNAB-based treatment and prevention of HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,791,377 | July 7, 2021 | June 30, 2026 | SAJADI, MOHAMMAD MOHSENI | reporter.nih.gov |
| Investigation into the activation of multiple bnAb precursors using structure-designed immunogens and Ig knock-in mice | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,732,799 | November 3, 2022 | October 31, 2027 | ESCOLANO, AMELIA | reporter.nih.gov |
| The functional significance of CTL escape | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,672,973 | April 1, 2003 | November 30, 2025 | WATKINS, DAVID I | reporter.nih.gov |
| B cell lineage directed rational vaccine strategies based on CAP256SU Env-Ab coevolution | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,664,383 | May 4, 2022 | May 31, 2026 | ANDRABI, RAIEES AHMAD | reporter.nih.gov |
| Fusion peptide directed immunogens that elicit neutralizing and protective antibodies in non-human primates | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,658,042 | March 18, 2019 | February 28, 2025 | WARD, ANDREW BARRETT | reporter.nih.gov |
| " Investigating the Protective Efficacy of SIV/HIV T and B cell Immunity Induced by RNA Replicons.” | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,651,252 | March 1, 2023 | February 28, 2027 | GAIHA, GAURAV DAS | reporter.nih.gov |
| Technologies for High-Throughput Mapping of Antigen Specificity to B-Cell-Receptor Sequence | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,524,989 | May 19, 2023 | April 30, 2028 | GEORGIEV, IVELIN | reporter.nih.gov |
| Nonhuman Primate Core Humoral Immunology Laboratory for AIDS Vaccine Research and Development | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,523,410 | March 30, 2025 | March 29, 2032 | SHEN, XIAOYING | reporter.nih.gov |
| Developing robust and scalable genomics tools and databases to analyze immune receptor repertoires across broad populations | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,513,983 | February 10, 2023 | January 31, 2029 | ALACHKAR, HOUDA | reporter.nih.gov |
| Exploring the membrane-related components of HIV-1 Env for immunogen design | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,409,945 | July 24, 2023 | June 30, 2027 | CHEN, BING | reporter.nih.gov |
| Neutralization of primary HIV-1 viruses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,401,711 | May 1, 1994 | May 31, 2028 | MOORE, JOHN P | reporter.nih.gov |
| HIV-1 Env protein structure and function assessed by parallel smFRET and cryoET | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,392,094 | July 18, 2019 | June 30, 2028 | MOTHES, WALTHER H | reporter.nih.gov |
| Prenatal behavioral intervention to prevent maternal cytomegalovirus in pregnancy | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2021 to 2024 | $2,388,633 | June 10, 2020 | March 31, 2026 | FOWLER, KAREN B | reporter.nih.gov |
| High-resolution definition of B cell responses to HIV Env for immunogen design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,388,312 | January 1, 2013 | March 31, 2025 | LI, YUXING | reporter.nih.gov |
| Assessing HIV-1 Broadly Neutralizing Antibody Association Pathways for Vaccine Immunogen Design | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,372,300 | August 1, 2021 | July 31, 2026 | HENDERSON, RORY | reporter.nih.gov |
| Resource Support Program for AIDS Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,343,420 | April 8, 2025 | April 7, 2026 | reporter.nih.gov | |
| Integration of adjuvant derived nanoparticles and engineered mRNA for HIV vaccine discovery | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,322,184 | December 9, 2022 | November 30, 2027 | DONG, YIZHOU | reporter.nih.gov |
| Human Plasma Cell Maturation & Maintenance through CD138, TNFRSF, and Modulation of Ig Secretion | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,306,663 | February 21, 2023 | January 31, 2028 | LEE, FRANCES EUN-HYUNG | reporter.nih.gov |
| A Multifunctional Point of- Care Platform to Differentiate HIV Infection from Vaccine Induced Seropositivity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,299,994 | November 1, 2024 | October 31, 2027 | NG, RANIER | reporter.nih.gov |
| Sex difference in intestinal immune dysfunction, SHIV infection and reservoir | NIH | National Institute of Diabetes and Digestive and Kidney Diseases | 2023 to 2025 | $2,261,633 | August 15, 2021 | June 30, 2027 | CHANG, THERESA L | reporter.nih.gov |
| Potent broadly neutralizing antibody development against the HIV-1 fusion peptide epitope | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,255,355 | September 21, 2023 | July 31, 2028 | DEKOSKY, BRANDON JAMES | reporter.nih.gov |
| Blocking granzyme-mediated immune suppression to enhance HIV vaccine efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,240,726 | March 13, 2023 | February 28, 2027 | WAGGONER, STEPHEN N. | reporter.nih.gov |
| Sublingual Supramolecular Vaccines and Immunotherapies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,219,609 | September 20, 2021 | August 31, 2026 | COLLIER, JOEL H | reporter.nih.gov |
| IL-27-producing B cells in the antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,209,265 | February 2, 2021 | January 31, 2027 | XU, ZHENMING | reporter.nih.gov |
| Mechanisms of protective memory CD8 T-cell induction by mRNA-LNP vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,140,211 | June 1, 2023 | May 31, 2028 | SIGAL, LUIS J | reporter.nih.gov |
| Impact of immune sex differences in the first 1000 days of life and in childhood and adolescence | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,131,407 | June 17, 2022 | May 31, 2027 | GOULDER, PHILIP J | reporter.nih.gov |
| Manipulating & imaging nutrient micro-milieux as B cells effect humoral immunity | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $2,101,327 | December 1, 2019 | November 30, 2025 | BOOTHBY, MARK R | reporter.nih.gov |
| Statistical Methods for Efficacy Trials of Vaccines and Monoclonal Antibodies Against Genetically-Diverse Pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $2,067,031 | April 1, 2003 | June 30, 2029 | GILBERT, PETER B. | reporter.nih.gov |
| Functional Omics Core Laboratory | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $2,065,495 | May 15, 2025 | May 14, 2026 | BOSINGER, STEVEN EDWARD | reporter.nih.gov |
| Adjuvant, mimicry and booster requirements for shepherding the development of neutralizing antibodies to the high-mannose patch on HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $2,061,489 | September 1, 2017 | July 31, 2027 | PANTOPHLET, RALPH ALPHONSO | reporter.nih.gov |
| Multiscale Computational Microscopy of HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,033,832 | July 7, 2023 | June 30, 2028 | AMARO, ROMMIE E | reporter.nih.gov |
| How antigen exposure shapes the subsequent NK cell response to HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $2,023,842 | March 18, 2021 | February 28, 2026 | PAUST, SILKE | reporter.nih.gov |
| Nanovaccine for Eliciting bnAbs Against HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $2,000,000 | July 1, 2024 | June 30, 2027 | RAYCHAUDHURI, SANTANU | reporter.nih.gov |
| Design and Engineering of VesiVax HIV Immunogen Formulations | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $1,999,866 | July 1, 2024 | June 30, 2026 | HO, SAMON | reporter.nih.gov |
| Comprehensive characterization of immune signaling networks in single-cells by joint quantification of proteins, protein complexes and mRNA | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,999,024 | February 17, 2023 | January 31, 2028 | TAY, SAVAS | reporter.nih.gov |
| Molecular control of germinal center selection and affinity maturation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,993,832 | August 15, 2018 | May 31, 2029 | VICTORA, GABRIEL D | reporter.nih.gov |
| Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,963,600 | April 9, 2021 | April 30, 2027 | KHANDHAR, AMIT PRAFUL | reporter.nih.gov |
| Engineering of pan-neutralizing anti-HIV envelope antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,919,991 | December 5, 2019 | November 30, 2025 | SAJADI, MOHAMMAD MOHSENI | reporter.nih.gov |
| Intrarectal Immunization for a Barrier to Mucosal HIV Infection | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,888,173 | April 19, 2024 | February 28, 2029 | GAUDUIN, MARIE-CLAIRE ELISABETH | reporter.nih.gov |
| Revealing the Biophysics of the Germinal Center Microenvironment | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,886,400 | December 22, 2021 | November 30, 2026 | ABBOTT, ROBERT KOEHLER | reporter.nih.gov |
| Characterization of HIV-1 IgA bNAbs and ADCP function | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,883,154 | September 1, 2022 | December 15, 2024 | WU, XUELING | reporter.nih.gov |
| Combining membrane Env vaccine regimens to elicit multiple bnAb lineages and consistent cross-neutralization of HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,866,100 | December 1, 2023 | October 31, 2028 | ZWICK, MICHAEL B | reporter.nih.gov |
| Feasibility for Development of a Liposome/LNP Displaying an HIV Env Trimer Protein and Containing/Incorporating an mRNA | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $1,863,405 | August 31, 2024 | August 27, 2028 | FOUTS, TIMOTHY R | reporter.nih.gov |
| Signaling and Selection in Germinal Center B Cells | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,852,493 | March 15, 2014 | February 28, 2025 | SHLOMCHIK, MARK J | reporter.nih.gov |
| Preclinical and Translational Vaccine Development for HIV and Other Candidate Agents (PTVDS) | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $1,829,809 | December 1, 2024 | November 30, 2025 | KENNEDY, MICHELLE | reporter.nih.gov |
| Characterizing antibody responses to HIV-1 vaccination in next-generation immune humanized mice | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,817,711 | March 21, 2023 | February 28, 2027 | GOETTEL, JEREMY ALLEN | reporter.nih.gov |
| Mwanza-Tanzania Research Training Program in HIV Clinical Investigation | NIH | Fogarty International Center | 2021 to 2025 | $1,808,742 | April 1, 2021 | March 31, 2027 | FITZGERALD, DANIEL W | reporter.nih.gov |
| HIV mRNA vaccine strategies for efficient priming, diversity and durability of immune responses | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,767,184 | April 1, 2024 | March 31, 2027 | RAMEZANI-RAD, PARHAM | reporter.nih.gov |
| An Env apex-focused HIV-1 vaccine strategy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,758,780 | July 24, 2024 | May 31, 2029 | FARZAN, MICHAEL R. | reporter.nih.gov |
| Transcriptional and metabolic regulation of vaccine-elicited CD8+ T cell responses | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2025 | $1,698,485 | January 1, 2007 | March 31, 2029 | KEDL, ROSS M | reporter.nih.gov |
| Immune engineering of optimized sequential immunization strategies for HIV vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,687,928 | April 1, 2021 | June 30, 2026 | IRVINE, DARRELL J | reporter.nih.gov |
| Harnessing native glycosylation to improve immunogenicity of HIV-1 Env immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,685,857 | April 16, 2024 | March 31, 2029 | UPADHYAY, CHITRA | reporter.nih.gov |
| Eliciting Broadly Neutralizing Antibody Responses against HIV-1 Fusion Peptide Epitope by AB Toxin B Subunit-Based Immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,684,444 | August 2, 2024 | July 31, 2029 | KONG, XIANGPENG | reporter.nih.gov |
| The role for ER associated degradation (ERAD) in T cell homeostasis and memory | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,662,297 | March 17, 2023 | February 29, 2028 | CARTY, SHANNON A. | reporter.nih.gov |
| Comparison of Bivalent vs Pentavalent Subtype C Envelope HIV-1 Vaccine Efficacy Following Mucosal Virus Challenge | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,657,533 | August 15, 2016 | June 30, 2021 | SILVERA, PETER | reporter.nih.gov |
| Leveraging membrane Env liposome vaccine design to elicit multi-target cross-neutralization of HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,655,736 | March 18, 2024 | February 29, 2028 | ZWICK, MICHAEL B | reporter.nih.gov |
| Neonatal Immunity to novel TF SHIVs | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,624,728 | August 15, 2018 | January 31, 2029 | WILLIAMS, WILTON B | reporter.nih.gov |
| Inferring the rules of antibody evolution using replicated germinal centers | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,624,708 | July 1, 2024 | May 31, 2029 | VICTORA, GABRIEL D | reporter.nih.gov |
| Mechanisms and means to improve HIV bnAb activity in vivo | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,608,066 | August 20, 2024 | July 31, 2029 | ACKERMAN, MARGARET E | reporter.nih.gov |
| Deep Learning-based Protein Design of HIV-1 Env GP120 Core Immunogens for CD4 Binding Site Germline Targeting | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,604,893 | February 16, 2024 | January 31, 2028 | PANCERA, MARIE | reporter.nih.gov |
| Advancing Multi-bNAbs Microneedle Patch Technology For HIV-1 Prevention in Breastfeeding Infants. | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,597,030 | August 29, 2024 | June 30, 2029 | DONCEL, GUSTAVO F. | reporter.nih.gov |
| SHIV-guided design of novel HIV-1 fusion peptide immunogens | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,591,028 | March 21, 2024 | February 29, 2028 | SHAW, GEORGE M | reporter.nih.gov |
| AAV Vectored Delivery of Broadly Neutralizing Antibodies with Optimal Innate Functionality Against HIV | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $1,578,174 | June 15, 2023 | May 31, 2025 | BALAZS, ALEJANDRO BENJAMIN | reporter.nih.gov |
| Investigation of Synthetic DNA-based Viral Particles for Spatially Controlled Antigen Presentation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,551,000 | August 2, 2021 | July 31, 2025 | BATHE, MARK | reporter.nih.gov |
| Epigenetic instruction of memory B cell function and reactivation | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,548,088 | December 12, 2019 | November 30, 2024 | SCHARER, CHRISTOPHER D | reporter.nih.gov |
| Vectored delivery of anti-HIV antibodies for mucosal protection | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,548,010 | March 14, 2023 | February 28, 2027 | MARTINEZ-NAVIO, JOSE MARIA | reporter.nih.gov |
| Harnessing CD4 T follicular helper 1 cells for HIV vaccine efficacy | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,547,287 | August 1, 2024 | June 30, 2029 | IYER, SWAMINATHAN SMITA | reporter.nih.gov |
| Exploiting glycan holes and sequence diversity of naturally occurring HIV envelope towards the design of vaccine immunogen panels for induction of neutralization breadth | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,545,149 | August 20, 2024 | June 30, 2029 | DERDEYN, CYNTHIA ANN | reporter.nih.gov |
| Hydrogel-Based Aged Immune Organoids to Study Epigenetics and Trajectory of B Cells | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,512,629 | July 12, 2024 | May 31, 2029 | SINGH, ANKUR | reporter.nih.gov |
| Combinatorial and computational design of bnAb mRNA vaccines for HIV | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,497,172 | April 7, 2021 | May 31, 2027 | ANDERSON, DANIEL G | reporter.nih.gov |
| GLP Toxicology Study for Adjuvanted HIV-1 Immunogen Vaccine Candidates | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,428,706 | February 1, 2025 | August 1, 2028 | BUNIN, DEBORAH | reporter.nih.gov |
| Globally Appropriate Genome Reduced Killed Whole Bacterial HIV Vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,413,125 | March 13, 2023 | February 28, 2027 | ZEICHNER, STEVEN L. | reporter.nih.gov |
| Origins and dynamics of HIV gp120 specific B cell memory in HIV negative high-risk individuals | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,409,901 | August 1, 2024 | June 30, 2029 | KOBIE, JAMES J | reporter.nih.gov |
| The evolutionary landscape of HIV broadly neutralizing antibody development | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,386,000 | August 24, 2023 | July 31, 2028 | STARR, TYLER NELSON | reporter.nih.gov |
| Engineering durable immunity by optimizing HIV vaccine parameters to drive long-lived plasma cell development | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,379,954 | August 21, 2025 | July 31, 2030 | BRINEY, BRYAN | reporter.nih.gov |
| T lymphocyte-mediated protection of the reproductive mucosa | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,350,666 | April 10, 2024 | February 28, 2029 | BEURA, LALIT K | reporter.nih.gov |
| Antigenic and virological traits of HIV-1 breakthrough infections in the VRC01 antibody-mediated prevention Phase 2b trial in sub-Saharan Africa | NIH | National Institute of Allergy and Infectious Diseases | 2021 to 2024 | $1,338,374 | April 17, 2020 | March 31, 2026 | WILLIAMSON, CAROLYN | reporter.nih.gov |
| Enhancing durability of V3 glycan vaccine responses in rhesus macaques | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,285,304 | August 1, 2025 | July 31, 2030 | STEICHEN, JON | reporter.nih.gov |
| An early life multivalent immunization strategy for induction of neutralization breadth | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,275,484 | August 12, 2025 | June 30, 2030 | NELSON, ASHLEY NICOLE | reporter.nih.gov |
| Leveraging prenatal tolerance to improve AAV/bNAb therapy outcomes in infancy | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,257,182 | August 1, 2025 | June 30, 2030 | MARTINS, MAURICIO A | reporter.nih.gov |
| Mechanisms of Early-life Immunity Associated with HIV-1 Vaccine-induced Neutralizing Antibody Responses | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1,239,565 | August 20, 2025 | June 30, 2030 | WILLIAMS, WILTON B | reporter.nih.gov |
| Guiding the maturation of anti-CD4-BS bnAbs through sequential heterologous Env immunization | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,222,090 | April 1, 2024 | February 28, 2029 | STAMATATOS, LEONIDAS | reporter.nih.gov |
| Tissue-specific adaptions to promote localized T cell memory | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,214,291 | November 8, 2023 | October 31, 2028 | GOLDRATH, ANANDA W | reporter.nih.gov |
| Mucosal T cell memory to pathogens | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,142,970 | February 1, 2010 | July 31, 2029 | MASOPUST, DAVID | reporter.nih.gov |
| RNA associated mechanisms for antigen receptor gene diversification during immature B cell development | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,137,074 | June 24, 2024 | April 30, 2029 | BASU, UTTIYA | reporter.nih.gov |
| Genome organization, evolutionary structural variation, and gene regulation in immunity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,093,335 | June 4, 2024 | December 31, 2027 | WEINMANN, AMY SUSAN | reporter.nih.gov |
| Armed nanobodies as anti-infectives and anti-tumor agents | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,085,800 | July 19, 2024 | May 31, 2029 | WU, HAO | reporter.nih.gov |
| Epigenetic regulation of early B cell differentiation | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $1,083,882 | June 12, 2024 | April 30, 2029 | BOSS, JEREMY M. | reporter.nih.gov |
| Glycopeptide-specific helper T cells eliciting protective humoral immunity against HIV - Resubmission | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $1,024,570 | March 10, 2021 | February 28, 2027 | AVCI, FIKRI Y | reporter.nih.gov |
| "Extended dosing" immunization to enhance humoral immunity to next-generation vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $938,886 | February 14, 2023 | January 31, 2025 | IRVINE, DARRELL J | reporter.nih.gov |
| Broadly neutralizing antibody combinations with single virions in HIV+ plasma | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2025 | $921,851 | January 23, 2023 | December 31, 2026 | RAY, KRISHANU | reporter.nih.gov |
| Virology Core Laboratory (VCL) | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $918,144 | December 15, 2024 | December 14, 2025 | DENNY, THOMAS | reporter.nih.gov |
| Advancing HIV Vaccine Development with a Lipid Nanodisc Platform | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $910,905 | July 1, 2025 | February 12, 2026 | RANTALAINEN, KIMMO ILMARI | reporter.nih.gov |
| Complete mapping of immune selection from antibodies to HIV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $884,813 | December 7, 2018 | November 30, 2025 | BLOOM, JESSE D | reporter.nih.gov |
| Probing real-time conformational dynamics and allosteric cooperativity of the HIV-1 envelope glycoprotein during virus entry | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $880,911 | December 1, 2023 | October 31, 2028 | LU, MAOLIN | reporter.nih.gov |
| Preclinical and Translational Vaccine Development Support for HIV and Other Candidate Agents: Scientific, Quality and Regulatory Support Services | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $868,590 | August 8, 2025 | August 7, 2026 | MALLOY, DAVID | reporter.nih.gov |
| Immune engineering of optimized sequential immunization strategies for HIV vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $810,280 | April 1, 2021 | March 31, 2025 | IRVINE, DARRELL J | reporter.nih.gov |
| Characterization of HIV-1 IgA bNAbs and ADCP function | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $807,667 | September 1, 2022 | November 30, 2026 | WU, XUELING | reporter.nih.gov |
| Persistent Immunogenicity of IDLV delivering Gag and membrane tethered HIV-1 Envelope Trimers | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $791,661 | August 1, 2025 | July 31, 2030 | BLASI, MARIA | reporter.nih.gov |
| Molecular determinants of vaccine-induced antibody durability | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $777,495 | September 20, 2025 | July 31, 2030 | SAJADI, MOHAMMAD MOHSENI | reporter.nih.gov |
| Advancing communication strategies to support future HIV vaccine use among African Americans in the South. | NIH | National Institute on Minority Health and Health Disparities | 2024 | $766,932 | August 17, 2023 | April 1, 2025 | RITCHWOOD, TIARNEY D | reporter.nih.gov |
| Pushing HIV-1 Vaccine Protection to the Mucosal Barrier | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $745,752 | July 19, 2024 | May 31, 2025 | BARRY, MICHAEL A | reporter.nih.gov |
| Extended Stability Program Testing of Two Adenoviral HIV Vaccine Candidates | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $697,945 | September 16, 2022 | May 31, 2025 | EYLER, JESSICA | reporter.nih.gov |
| MEPCS (Multi-epitope protease cleavage sites) vaccine for protecting against SIV rectal transmission | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $657,563 | July 1, 2025 | June 30, 2029 | LI, QINGSHENG | reporter.nih.gov |
| MEPCS (Multi-epitope protease cleavage sites) vaccine for protecting against SIV rectal transmission | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $650,156 | August 21, 2024 | June 30, 2029 | LI, QINGSHENG | reporter.nih.gov |
| Mesenchymal stem/stromal cells to enhance cytotoxic T cell immunity during HIV infection | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $640,250 | December 15, 2022 | November 30, 2025 | KOL, AMIR | reporter.nih.gov |
| Genome organization, evolutionary structural variation, and gene regulation in immunity | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $608,007 | January 26, 2023 | May 8, 2024 | WEINMANN, AMY SUSAN | reporter.nih.gov |
| Demystifying the antiviral activity of the IgG3+ antibody response | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $604,801 | July 1, 2008 | December 31, 2025 | JUELG, BORIS DOMINIK | reporter.nih.gov |
| Simian Vaccine Evaluation Unit (SVEU) - Animal Maintenance and Care | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2025 | $549,792 | May 1, 2016 | April 30, 2019 | WEISS, DEBORAH | reporter.nih.gov |
| Novel humanized mouse model of mucosal immunity | NIH | Office of the Director, National Institutes of Health | 2023 to 2024 | $525,000 | January 1, 2023 | December 31, 2024 | PALUCKA, ANNA KAROLINA | reporter.nih.gov |
| Enhancing HIV-1 vaccines by altering vaccine dose | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $498,659 | August 1, 2024 | July 31, 2025 | PENALOZA, PABLO | reporter.nih.gov |
| Mechanism of HIV-1 Env neutralization by antibodies targeting the membrane-proximal external region | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $483,825 | August 12, 2025 | July 31, 2027 | QIN, ZHUAN | reporter.nih.gov |
| The Notch Pathway in Antigen Design | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $471,742 | August 18, 2023 | July 31, 2025 | ALLMAN, DAVID M | reporter.nih.gov |
| Epigenetic Histone Landscape Profiles in HIV | NIH | National Institute of Allergy and Infectious Diseases | 2022 to 2024 | $463,003 | July 21, 2022 | June 30, 2025 | UTZ, PAUL JOSEPH | reporter.nih.gov |
| A Mouse Model to Test the Effects of Gender-affirming Hormone Therapy on HIV Vaccine-induced Immune Responses | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $455,120 | May 26, 2023 | April 30, 2025 | CAIN, DEREK WILSON | reporter.nih.gov |
| "Extended dosing" immunization to enhance humoral immunity to next-generation vaccines | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $454,147 | February 14, 2023 | January 31, 2028 | IRVINE, DARRELL J | reporter.nih.gov |
| Interrogating mucosal resident memory CD8 T cell biology with 3D organoids | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $450,169 | May 21, 2024 | March 31, 2027 | BEURA, LALIT K | reporter.nih.gov |
| Mannosidase-stabilized glycan immunogens for elicitation of high mannose patch antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $446,875 | April 1, 2023 | March 31, 2026 | KRAUSS, ISAAC JONATHAN | reporter.nih.gov |
| Synergizing neutralization and non-neutralization antibody targets at the HIV/SIV viral spike apex | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $440,700 | August 9, 2024 | June 30, 2027 | CARDOZO, TIMOTHY J | reporter.nih.gov |
| Enhanced Antibody-Dependent Cellular Cytotoxicity in HIV Vaccine by Novel Adjuvant | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $433,125 | August 21, 2025 | July 31, 2027 | LIYANAGE, NAMAL | reporter.nih.gov |
| Overcoming preexisting antibodies to recombinant AAV vectors in rhesus macaques | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $432,049 | April 5, 2024 | February 28, 2027 | MARTINEZ-NAVIO, JOSE MARIA | reporter.nih.gov |
| Engineering mono-fucosylated IgGs to fine-tune antibody-mediated effector functions | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $430,375 | February 3, 2023 | January 31, 2025 | SUNDBERG, ERIC JOHN | reporter.nih.gov |
| Developmental layers of CD8+ T cells in the lymph node | NIH | National Institute of Allergy and Infectious Diseases | 2023 to 2024 | $430,203 | February 3, 2023 | January 31, 2025 | RUDD, BRIAN DAVID | reporter.nih.gov |
| Development of a novel mucosal CTL-based HIV vaccine. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $423,500 | August 1, 2025 | July 31, 2027 | QIAO, LIANG | reporter.nih.gov |
| HIV Vaccine Design Incorporating Selective Avidity | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $410,813 | August 7, 2024 | June 30, 2027 | MACPHERSON, IAIN SEIDO | reporter.nih.gov |
| CD38 intensifies immune activation in women living with HIV (the CIGNAL study) | NIH | Eunice Kennedy Shriver National Institute of Child Health & Human Development | 2024 to 2025 | $386,250 | July 15, 2024 | June 30, 2027 | MATHUR, POONAM | reporter.nih.gov |
| Novel Stealth Lipid for use in HIV MPER Vaccine | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $303,173 | September 1, 2025 | August 31, 2026 | HUCKNALL, ANGUS | reporter.nih.gov |
| coRNAucopia - A Method to Deliver Multiple bNAbs in the Same RNA | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $300,000 | August 15, 2024 | August 14, 2025 | HARLOW, MARK LEE | reporter.nih.gov |
| Development of a Next-Generation Immunoprevention Platform Against HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $300,000 | August 1, 2024 | July 31, 2025 | RAYCHAUDHURI, SANTANU | reporter.nih.gov |
| Vector-Based Delivery of HIV Broadly Neutralizing Antibodies | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $300,000 | August 1, 2024 | July 31, 2025 | MILLER, JACQUELINE | reporter.nih.gov |
| High-Dose and Sustained Delivery of HIV-1 Broadly Neutralizing Antibodies via Subcutaneous Injection of Hydrogel-based Microparticle Formations | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $295,116 | August 1, 2024 | July 31, 2025 | FORESTI, DANIELE | reporter.nih.gov |
| Clonal lineage tracing of HIV specific NK memory cells | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $220,000 | May 22, 2025 | April 30, 2027 | OVERBAUGH, JULIE M. | reporter.nih.gov |
| Targeting Tfh differentiation to increase the magnitude and durability of antibody responses in infant rhesus macaques after SHIV infection | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $214,996 | September 1, 2025 | August 31, 2028 | MITCHELL, JULIE | reporter.nih.gov |
| Multivalent mRNA HIV vaccine using Envelopes from recently circulating viruses. | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $208,875 | August 1, 2025 | July 31, 2028 | MIELKE, DIETER | reporter.nih.gov |
| "Evaluating the role of monocytes in the development of an effective HIV vaccine response" | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $174,296 | July 1, 2024 | June 30, 2027 | SIMPSON, RACHEL MARIE | reporter.nih.gov |
| Development and characterization of germline-targeted nanoparticle immunogens toward a novel HIV Env epitope | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $90,288 | January 16, 2024 | January 15, 2027 | CARTER, JOSH | reporter.nih.gov |
| The Role of Immunoglobulin Genetic Diversity in the Development of Neutralizing Antibodies Against HIV Env Protein | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $76,085 | March 1, 2024 | June 23, 2025 | EDWARDS, CHRISTOPHER | reporter.nih.gov |
| Development of soluble and membrane bound immunogens to shepherd HIV-1 MPER specific BCR maturation | NIH | National Institute of Allergy and Infectious Diseases | 2024 to 2025 | $72,512 | August 2, 2024 | August 1, 2027 | SWANSON, OLIVIA | reporter.nih.gov |
| Tracking B cell:Antigen Interactions for HIV-1 Vaccine Development | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $49,538 | September 1, 2025 | August 31, 2028 | KRIEWS, AUSTIN | reporter.nih.gov |
| Understanding Memory B Cell Formation and Reactivation in HIV Vaccine Strategies | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $38,936 | September 1, 2025 | August 31, 2027 | WEIDNER, NICOLE | reporter.nih.gov |
| Harnessing SHIVs and Sequential Immunization to Elicit V3 Glycan-Targeted bNAbs against HIV-1 | NIH | National Institute of Allergy and Infectious Diseases | 2024 | $36,512 | September 1, 2024 | August 31, 2025 | SKELLY, ASHWIN NICHOLAS | reporter.nih.gov |
| Roles of vaccine perturbations on germinal center dynamics | NIH | National Institute of Allergy and Infectious Diseases | 2025 | $1 | June 5, 2025 | June 6, 2025 | FREEMAN, BRIAN LUIS | reporter.nih.gov |
Organizations
| Organization | Place | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|---|
| Fred Hutchinson Cancer Center | Seattle, WA | 11 | $598.4 million | 0 | $0 |
| Duke University | Durham, NC | 18 | $222.1 million | 0 | $0 |
| Family Health International | Durham, NC | 1 | $213.6 million | 0 | $0 |
| PPD Development LP | Wilmington, NC | 1 | $198.6 million | 0 | $0 |
| Scripps Research Institute, the | La Jolla, CA | 15 | $179.6 million | 0 | $0 |
| Icahn School of Medicine at Mount Sinai | New York, NY | 4 | $114.3 million | 0 | $0 |
| Emory University | Atlanta, GA | 13 | $68.8 million | 0 | $0 |
| Technical Resources International, Inc. | Bethesda, MD | 2 | $52.4 million | 0 | $0 |
| Fisher Bioservices, Inc. | Rockville, MD | 1 | $46.9 million | 0 | $0 |
| Advanced Bioscience Laboratories, Inc. | Kensington, MD | 4 | $41.3 million | 0 | $0 |
| Weill Medical Coll of Cornell Univ | New York, NY | 5 | $37.7 million | 0 | $0 |
| University of Pennsylvania | Philadelphia, PA | 10 | $37 million | 0 | $0 |
| Tulane University of Louisiana | New Orleans, LA | 3 | $22.8 million | 0 | $0 |
| University of California, San Francisco | San Francisco, CA | 1 | $21.6 million | 0 | $0 |
| Brigham and Women's Hospital | Boston, MA | 1 | $21.4 million | 0 | $0 |
| Vanderbilt University Medical Center | Nashville, TN | 4 | $19.2 million | 0 | $0 |
| Columbia University Health Sciences | New York, NY | 4 | $19.1 million | 0 | $0 |
| University of Pittsburgh at Pittsburgh | Pittsburgh, PA | 3 | $16.5 million | 0 | $0 |
| University of Alabama at Birmingham | Birmingham, AL | 5 | $16.3 million | 0 | $0 |
| University of Washington | Seattle, WA | 3 | $15.8 million | 0 | $0 |
| Asociacion Civil Impacta Salud Y Educacn | Lima | 1 | $15.5 million | 0 | $0 |
| Wits Health Consortium (pty), LTD | Parktown | 1 | $15.1 million | 0 | $0 |
| University of Cape Town | Rondebosch | 2 | $14.9 million | 0 | $0 |
| Quality Biological, Inc. | Gaithersburg, MD | 2 | $13.9 million | 0 | $0 |
| University of Louisiana at Lafayette | Lafayette, LA | 1 | $13.8 million | 0 | $0 |
| Henry M. Jackson FDN for the Adv Mil/med | Bethesda, MD | 2 | $13.2 million | 0 | $0 |
| Centre/aids Programme/res/south Africa | Durban | 1 | $11.3 million | 0 | $0 |
| Johns Hopkins University | Baltimore, MD | 1 | $11.2 million | 0 | $0 |
| Boston Children's Hospital | Boston, MA | 4 | $10.4 million | 0 | $0 |
| University of Rochester | Rochester, NY | 2 | $10.3 million | 0 | $0 |
| University of Maryland Baltimore | Baltimore, MD | 6 | $9.2 million | 0 | $0 |
| Bioqual, Inc. | Rockville, MD | 2 | $9 million | 0 | $0 |
| Public Health Foundation Enterprises | City Of Industry, CA | 1 | $8.3 million | 0 | $0 |
| Fundacao Oswaldo Cruz | Rio de Janeiro | 1 | $8.2 million | 0 | $0 |
| International Aids Vaccine Initiative | New York, NY | 1 | $8 million | 0 | $0 |
| Massachusetts General Hospital | Boston, MA | 4 | $7.1 million | 0 | $0 |
| University of Florida | Gainesville, FL | 3 | $7.1 million | 0 | $0 |
| Aurum Institute NPC | Parktown, Johannesburg | 1 | $6.7 million | 0 | $0 |
| Texas Biomedical Research Institute | San Antonio, TX | 2 | $6.6 million | 0 | $0 |
| Rockefeller University | New York, NY | 3 | $6.6 million | 0 | $0 |
| J. David Gladstone Institutes | San Francisco, CA | 2 | $6.5 million | 0 | $0 |
| La Jolla Institute for Immunology | La Jolla, CA | 3 | $6.2 million | 0 | $0 |
| University of Chicago | Chicago, IL | 3 | $6 million | 0 | $0 |
| University of Miami School of Medicine | Coral Gables, FL | 3 | $5.8 million | 0 | $0 |
| University of Michigan at Ann Arbor | Ann Arbor, MI | 2 | $5.2 million | 0 | $0 |
| Massachusetts Institute of Technology | Cambridge, MA | 4 | $4.8 million | 0 | $0 |
| Boston Medical Center | Boston, MA | 2 | $4.3 million | 0 | $0 |
| San Diego Biomedical Research Institute | San Diego, CA | 1 | $4.1 million | 0 | $0 |
| University of Minnesota | Minneapolis, MN | 2 | $4 million | 0 | $0 |
| Ohio State University | Columbus, OH | 2 | $3.4 million | 0 | $0 |
| Wistar Institute | Philadelphia, PA | 2 | $3.4 million | 0 | $0 |
| Children's Mercy Hosp (kansas City, Mo) | Kansas City, MO | 1 | $3.3 million | 0 | $0 |
| University of California, San Diego | La Jolla, CA | 2 | $3.2 million | 0 | $0 |
| Yale University | New Haven, CT | 2 | $2.9 million | 0 | $0 |
| George Washington University | Washington, DC | 1 | $2.7 million | 0 | $0 |
| Jackson Laboratory | Bar Harbor, ME | 2 | $2.5 million | 0 | $0 |
| University of Southern California | Los Angeles, CA | 1 | $2.5 million | 0 | $0 |
| Neovaxsyn, Inc. | Ames, IA | 2 | $2.3 million | 0 | $0 |
| Baebies, Inc. | Durham, NC | 1 | $2.3 million | 0 | $0 |
| Rutgers Biomedical and Health Sciences | Newark, NJ | 1 | $2.3 million | 0 | $0 |
| Cincinnati Childrens Hosp Med CTR | Cincinnati, OH | 1 | $2.2 million | 0 | $0 |
| University of Texas HLTH Science Center | San Antonio, TX | 1 | $2.2 million | 0 | $0 |
| Thomas Jefferson University | Philadelphia, PA | 1 | $2.1 million | 0 | $0 |
| University of Oxford | Oxford | 1 | $2.1 million | 0 | $0 |
| New York University School of Medicine | New York, NY | 2 | $2.1 million | 0 | $0 |
| Simon Fraser University | Burnaby | 1 | $2.1 million | 0 | $0 |
| Molecular Express, Inc. | Rancho Dominguez, CA | 1 | $2 million | 0 | $0 |
| HDT Bio Corporation | Seattle, WA | 1 | $2 million | 0 | $0 |
| University of Texas Med BR Galveston | Galveston, TX | 2 | $1.9 million | 0 | $0 |
| Midwest Research Institute | Kansas City, MO | 1 | $1.8 million | 0 | $0 |
| Brown University | Providence, RI | 2 | $1.8 million | 0 | $0 |
| University of Colorado Denver | Aurora, CO | 1 | $1.7 million | 0 | $0 |
| Dartmouth College | Hanover, NH | 1 | $1.6 million | 0 | $0 |
| Old Dominion University | Norfolk, VA | 1 | $1.6 million | 0 | $0 |
| Georgia Tech Research Corporation | Atlanta, GA | 1 | $1.5 million | 0 | $0 |
| Sri International | Menlo Park, CA | 1 | $1.4 million | 0 | $0 |
| University of Virginia | Charlottesville, VA | 1 | $1.4 million | 0 | $0 |
| University of Utah | Salt Lake City, UT | 1 | $1.4 million | 0 | $0 |
| University of Texas HLTH CTR at Tyler | Tyler, TX | 1 | $880,911 | 0 | $0 |
| Wake Forest University Health Sciences | Winston-Salem, NC | 1 | $766,932 | 0 | $0 |
| Mayo Clinic Rochester | Rochester, MN | 1 | $745,752 | 0 | $0 |
| Paxvax, Inc. | San Diego, CA | 1 | $697,945 | 0 | $0 |
| University of Nebraska-Lincoln | Lincoln, NE | 1 | $650,156 | 0 | $0 |
| University of California at Davis | Davis, CA | 1 | $640,250 | 0 | $0 |
| Stanford University | Stanford, CA | 2 | $553,291 | 0 | $0 |
| Northwestern University at Chicago | Chicago, IL | 1 | $498,659 | 0 | $0 |
| Brandeis University | Waltham, MA | 1 | $446,875 | 0 | $0 |
| Cornell University | Ithaca, NY | 1 | $430,203 | 0 | $0 |
| Loyola University Chicago | Maywood, IL | 1 | $423,500 | 0 | $0 |
| University of Hawaii | Honolulu, HI | 1 | $410,813 | 0 | $0 |
| Gateway Bio, Inc. | Durham, NC | 1 | $303,173 | 0 | $0 |
| Lynntech, Inc. | College Station, TX | 1 | $300,000 | 0 | $0 |
| Cure Systems LLC | Newton Center, MA | 1 | $300,000 | 0 | $0 |
| Acousticabio, Inc. | Cambridge, MA | 1 | $295,116 | 0 | $0 |
| Oregon Health & Science University | Portland, OR | 1 | $214,996 | 0 | $0 |
Funding by fiscal year
| Fiscal year | NIH awards | NIH amount | NSF awards | NSF amount |
|---|---|---|---|---|
| 2025 | 175 | $451,694,658 | 0 | $0 |
| 2024 | 195 | $454,106,183 | 0 | $0 |
| 2023 | 136 | $436,745,050 | 0 | $0 |
| 2022 | 105 | $642,522,853 | 0 | $0 |
| 2021 | 80 | $304,099,924 | 0 | $0 |
Open federal funding opportunities
From Grants.gov: notices that funded awards in this table, and open notices on the same agency and assistance listing.
| Open opportunity | Number | Agency | Listing | Closes | Award ceiling | Why it matches |
|---|---|---|---|---|---|---|
| Change of Recipient Organization (Type 7 Parent Clinical Trial Optional) | PA-24-254 | NIH | July 12, 2027 | Not listed | Notice number printed on 4 awards here | |
| Infectious Diseases Clinical Trials Network (IDCTN) (UM1 Clinical Trial Required) | RFA-AI-27-002 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Clinical Research Network on Antimicrobial Resistance (UM1 Clinical Trial Required) | RFA-AI-27-005 | NIH | 93.855 | November 10, 2026 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Ethical, Legal and Social Implications (ELSI) Small Research Grant (R03 Clinical Trial Optional) | PAR-25-370 | NIH | 93.855 | November 16, 2026 | $50,000 | Same assistance listing 93.855 as 181 awards here |
| Ethical, Legal and Social Implications (ELSI) Exploratory/Developmental Research Grant (R21 Clinical Trial Optional) | PAR-25-369 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Ethical, Legal and Social Implications (ELSI) Research (R01 Clinical Trial Optional) | PAR-25-371 | NIH | 93.855 | November 18, 2026 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Intervention Research to Improve Native American Health (R01 Clinical Trial Optional) | PAR-25-379 | NIH | 93.855 | January 7, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| HIV/AIDS Clinical Trials Network Leadership and Operations Centers | RFA-AI-28-001 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| HIV/AIDS Clinical Trials Network Laboratory Centers | RFA-AI-28-002 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| HIV/AIDS Clinical Trials Network Statistical and Data Management Centers | RFA-AI-28-003 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| HIV/AIDS Clinical Trials Network Clinical Trials Units | RFA-AI-28-004 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Precision and Systems Biology to Uncover the Link Between Chronic and Infectious Diseases | RFA-AI-28-014 | NIH | 93.855 | January 22, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Immune Tolerance Network (UM1 Clinical Trial Required) | RFA-AI-28-005 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Translational Centers Using Microphysiological Systems for Infectious Diseases (U54 Clinical Trial Not Allowed) | RFA-AI-28-012 | NIH | 93.855 | January 29, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Accelerating Research and Development of Next Generation Vaccines against Malaria - a Model for Mosquito-Borne Diseases (R61/R33 Clinical Trial Not Allowed) | RFA-AI-28-024 | NIH | 93.855 | February 11, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| NLM Institutional Grants for Research Training in Biomedical Informatics, Data Science, and AI (T15 Independent Clinical Trial Not Allowed) | RFA-LM-28-001 | NIH | 93.855 | February 11, 2027 | $775,000 | Same assistance listing 93.855 as 181 awards here |
| NIH, CDC and FDA Small Business Innovation Research Grant (Parent SBIR [R43/R44] Clinical Trial Optional) | PA-27-100 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| NIH Small Business Technology Transfer Grant (Parent STTR [R41/R42] Clinical Trial Optional) | PA-27-102 | NIH | 93.855 | April 5, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Mentored Research Scientist Development Award (Parent K01 - Independent Clinical Trial Not Allowed) | PA-24-176 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
| Mentored Patient-Oriented Research Career Development Award (Parent K23 Independent Clinical Trial Not Allowed) | PA-24-185 | NIH | 93.855 | May 7, 2027 | Not listed | Same assistance listing 93.855 as 181 awards here |
Updated November 3, 2026. Read from NIH RePORTER ExPORTER and NSF Award Search. Published by NIH and NSF as U.S. government data. NIH awards are fiscal years 2021 to 2025 (NIH files published to 2026-07-09); NSF awards are fiscal years 2022 to 2026 (NSF files published to 2026-11-02). NIH amounts are the total cost of each fiscal year in the window; NSF amounts are the funds obligated in the window. Organizations are matched on the UEI. Open opportunities come from Grants.gov and match on agency and assistance listing number, and on the notice number NIH prints on an award. Free to reuse with credit to SpecStream under CC BY 4.0. Spot a wrong value? Write to [email protected] with the link to this page.